Phase 1 N=28 A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
COVID-19
Primary: Subjects With Adverse Events (AEs) up to 3 Days Post-dosing — 3; 4; 6; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=179 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment — 1.27; 1.48 seconds — p==0.0345
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 3 N=399 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
N/A N=21 Neurally Targeted Cognitive Training to Augment CBT Outcomes in Pediatric Anxiety
Anxiety Disorders
Primary: Change in Brain Activation and Connectivity in the Task-control Network (TCN) — 0.020; -0.206; 0.305; -0.004 Arbitrary Units
Phase 2 N=16 SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity · Pre-diabetes
Primary: Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 3 Months — -1.6 Percentage of CD3+ T cells
N/A N=200 CareConekta: A Smartphone App to Improve Engagement in HIV Care
HIV/AIDS · Pregnancy Related
Primary: Mobility Prevalence — 30; 24; 54; 65 Participants
Phase 3 N=21 Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
N/A N=75 Safety and Performance Study of Large Hole Vascular Closure Device FIV
Percutaneous CFA Arteriotomy Closure
Primary: Major Vascular Complications [Safety] — 0 Participants — p=<.0001
Phase 2 N=98 A Study of LY3462817 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP) — -0.99; -1.88…
Phase 4 N=112 High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
Helicobacter Pylori Infection
Primary: Number of Participant With Eradication of Disease — 37; 42 Participants
N/A N=25 Breast Cup Immobilization Device II (GCC 1047)
Breast Cancer
Primary: Breast Cup Immobilization Device II (GCC 1047) Feasibility — 25 Participants
N/A N=172 Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program
Scleroderma · Scleroderma, Systemic · Systemic Sclerosis
Primary: Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 — 56.9; 58.8 T-score
N/A N=76 Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants